DAX24.217 +1,0%ESt505.379 +0,8%Top 10 Crypto15,90 -2,0%Dow44.633 -0,5%Nas21.098 -0,4%Bitcoin101.812 +0,2%Euro1,1550 ±0,0%Öl72,76 +3,4%Gold3.329 +0,1%

Galderma Aktie

Kaufen

Verkaufen

Handeln Handeln

138,00 EUR +2,00 EUR +1,47 %

29.07.2025

BMN

128,40 CHF -5,30 CHF -3,96 %

29.07.2025

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Smartphone

Marktkap.33,74 Mrd. EUR

KGV117,50Div. Rendite0,15%

WKNA407X6

ISINCH1335392721

SymbolGDERF

Galderma Aktien News

Sortieren:Datum Meistgelesen

17.03.25PR NewswireGalderma's Differin is helping destigmatize acne care with first in category Roblox experience

14.01.25BusinesswireGalderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

13.12.24BusinesswireGalderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

WerbungGalderma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.12.24BusinesswireCHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

28.11.24BusinesswireGalderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

04.11.24BusinesswireCelebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

25.10.24BusinesswireGalderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

24.10.24BusinesswireGalderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

21.10.24BusinesswireASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

29.08.24BusinesswireGalderma Successfully Issued an Inaugural CHF 500 Million Bond

13.08.24BusinesswireGalderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

05.08.24BusinesswireGalderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

30.07.24BusinesswireGalderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

25.07.24BusinesswireGalderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

25.07.24BusinesswirePHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance

19.06.24BusinesswireGalderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

23.05.24BusinesswireGalderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets

07.05.24BusinesswireGalderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries

24.04.24BusinesswireGalderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

26.03.24BusinesswireGalderma Announces Full Exercise of Over-Allotment Option

Galderma News

Galderma News: auf dieser Seite finden Sie alle Galderma News und Nachrichten zur Galderma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Galderma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Galderma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.